… effectiveness (VKA rates and comparative effectiveness). A previous … 18 cost-effectiveness
models comparing rivaroxaban and other NOACs with VKAs for stroke prevention in patients …

… cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke
prevention in atrial fibrillation in France. … Comparison of the cost-effectiveness of new oral …

… cost-effectiveness analyses were performed to compare … cost-effectiveness of
apixaban compared to other DOACs and VKAs (warfarin) to determine the incremental cost-effectiveness …

… Non valvular atrial fibrillation (NVAF) is the most common form of … In France, cost-effectiveness
studies have shown … This study aimed to compare HCRU and related costs associated to …

… useful information on the comparative effectiveness of DOACs. Because France has near-…
the comparative effectiveness of the OACs used in France for NVAF, focused on apixaban. …

… the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in
Japanese patients … of rivaroxaban compared to that of warfarin in patients with NVAF in Japan. …

… vitamin K antagonist for stroke prevention in non-valvular atrial fibrillation, from the Spanish
… by confounding in a non-randomised comparison, but are more likely explained by an effect …

… However, findings from the one-way sensitivity analyses indicated that variations in clinical
event costs did not have a high impact on the cost-effectiveness of apixaban relative to the …

… patients with atrial fibrillation (AF) remain unclear. This study aimed to estimate and compare
the cost-effectiveness … ; warfarin) in preventing stroke among AF patients aged >75 years in …

… cost effectiveness of direct-acting oral anticoagulants for stroke prevention in Thai patients
with non-valvular atrial … was performed by comparing an outcome of patient survival in the …